CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 13, 2020-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced the pricing of its underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $4.75 per

2021-03-30

Wall Street Stock Market & Finance report, prediction for the future: You'll find the Axcella Health share forecasts, stock quote and buy / sell signals below. According to present data Axcella Health's AXLA shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). About Axcella Stock Axcella Health is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has discovered more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular level.

Axcella stock

Find the latest Axcella Health Inc. (AXLA) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-03-30 Stock analysis for Axcella Health Inc (AXLA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 2021-03-17 Axcella Health Inc Registered Shs Stock , AXLA. Axcella Health Inc Registered Shs. Stock. , AXLA.

4 days ago Galaxy Digital Holdings Ltd. stock and Capital Markets market discussion, news, and analysis from Canada's largest community of active

It treats complex diseases and enhances health using endogenous metabolic modulator compositions. The company's lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis. 2021-04-09 · View Axcella Health Inc. AXLA investment & stock information.

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Axcella Health Inc. (AXLA) since 2019 are shown in Table 1 and

Botox powder for solution for injection SmPC Axcella Health shares have exploded 147.6% over the past year, while the stock still scores a Strong Buy consensus rating based on 4 unanimous Buys. That’s alongside an average analyst price target AXLA | Complete Axcella Health Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Get the latest Axcella Health Inc. AXLA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Axcella Health PRIVATE Updated Apr 9, 2021 11:08 PM. AXLA 4.34 0.24 (5.24%).
In group vs out group

Their average twelve-month price target is $16.13, suggesting a possible upside of 233.9%. Roth Capital has the highest price target set, predicting AXLA will reach $28.00 in the next twelve months. Company profile page for Axcella Health Inc including stock price, company news, press releases, executives, board members, and contact information Detailed statistics for Axcella Health (AXLA) stock, including valuation metrics, financial numbers, share information and more.

Piper Sandler have made an estimate for Axcella Health Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 31, 2020. While these analysts kept the previous recommendation, Wedbush raised their target price to Outperform. Axcella Health Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05454B105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☐ Rule 13d-1(c) ☒ Rule 13d The table below shows stocks similar to Axcella Health Inc., i.e, from same subsector or sector along with year-to-date (-6.9% YTD), weekly (-0.8%) & daily performaces for comparison.
Skumglas pris

Stock analysis for Axcella Health Inc (AXLA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

stock was originally listed at a price of $13.80 in May 9, 2019. If you had invested in Axcella Health stock at $13.80, your return over the last 1 years would have been -54.28%, for an annualized return of -54.28%. © Axcella Stock Performance (As of Tuesday Closing) Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS; $4.92: $5.34: $2.46 - $7.73: $185M: 37 Pioneering a new approach to treating complex diseases and supporting health using Endogenous Metabolic Modulators (EMMs). 2021-04-09 · Axcella Health PRIVATE Updated Apr 9, 2021 11:08 PM. AXLA 4.34 0.24 (5.24%).

Denna sida innehåller de senaste nyheterna om Axcella Health Inc aktien.

Aktien är noterad på Nasdaq Stock Exchange som AXLA . Uppgifter. Vill du veta mer om Axcella Health? Här är den information vi har om aktien:. Studio City International Holdings Limited American depositary shares, each representing four Class A ordinary shares · The Hackett Group, Inc. CNFinance MER Telemanagement Solutions Ltd. - Ordinary Shares · AMREP Corporation · Evercore Inc. Class A · Sierra Wireless, Inc. Exact Sciences Corporation. Find real-time AXLA - Axcella Health Inc stock quotes, company profile, news and forecasts from CNN Business. Next reporting date Ma EPS forecast (this Url: https://www.nordnet.se/marknaden/etf-listor/16477180-i-shares-sp-500 Go Now The shares are issued by companies in the health care sector.

Learn quickly and From beautifying your slideshow presentations at work to providing engaging visuals for your blog posts, stock photos are ideal resources for your graphic design and other needs. They’re easy to use and easy to access online, eliminating th Wondering how to actually buy stocks in the stock market? Learn the entire process from our market expects and feel confident in your decisions. Learn everything you need to know about successful options trading with this three-part video c Ever wondered how to buy stock in Axcella Health Inc? We explain how and compare the best share dealing platforms. Plus a detailed analysis of the biotechnology specialist's financials and forecast.